

FoI request re: Biologics and biosimilar prescribing

Ref: 19-SW-0910

Dear,

Thank you for your request for information relating to Biologics and biosimilar prescribing by specialty.

This was received on 23 September 2019 and has been dealt with under the terms of the Freedom of Information Act 2000.

Please find our responses below:

Treatment	Rheumatology	Dermatology	Gastroenterology
Abatacept (Orencia)	≤5		
Adalimumab biosimilar [Amgevita]	44	≤5	30
Adalimumab biosimilar [Hulio]			
Adalimumab [Humira]	54	≤5	31
Adalimumab biosimilar [Hyrimoz]	18		
Adalimumab biosimilar [Imraldi]			
Apremilast (Otezla)			
Baricitinib (Olumiant)			
Brodalumab (Kyntheum)			
Certolizumab (Cimzia)	7		
Dimethyl Fumarate (Skilarence)			
Etanercept (Enbrel)	12		
Etanercept Biosimilar (Benepali)	80		
Etanercept Biosimilar (Erelzi)			
Golimumab (Simponi)	13		20
Guselkumab (Tremfya)		≤5	
Infliximab [Flixabi]			
Infliximab [Inflectra]			
Infliximab [Remicade]	≤5		16
Infliximab [Remsima]	≤5		92
Ixekizumab (Taltz)			
Rituximab (Mabthera)			
Rituximab Biosimilar (Rixathon)			
Rituximab Biosimilar (Truxima)	44		
Sarilumab (Kevzara)			
Secukinumab (Cosentyx)	43	≤5	
Tildrakizumab (Ilumetri)			
Tocilizumab (Ro Actemra)	8		
Tofacitinib (Xeljanz)			
Ustekinumab (Stelara)	11	33	18

Whittington Health NHS Trust

Interim Chair: David Holt Chief Executive: Siobhan Harrington

Please note that the trust's policy is not to provide patient or staff numbers, where the response is less than or equal to five (≤ 5) as it would potentially allow identification of the individual patient/staff and would therefore be personal data. The trust considers that release of that information would breach GDPR/DPA18 principles on the grounds that it would not be fair in all the circumstances. This information is therefore exempt under section 40 of the FOI Act 2000.

Whittington Health NHS Trust

Interim Chair: David Holt Chief Executive: Siobhan Harrington